Sanara MedTech (SMTI) EBITDA (2010 - 2026)

Sanara MedTech's EBITDA history runs 16 years deep, the most recent figure standing at $4.3 million for Q1 2026.

• Quarterly EBITDA rose 58.15% year-over-year to $4.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.5 million (up 66.86% YoY) and the FY2025 annual result came in at $17.0 million, up 85.97% from the prior year.
• EBITDA was $4.3 million for Q1 2026 at Sanara MedTech, down from $4.7 million in the prior quarter.
• Across five years, EBITDA topped out at $4.9 million in Q3 2025 and bottomed at -$3.4 million in Q2 2022.
• A 5-year average of $789868.6 and a median of $448909.0 in 2023 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2022 — EBITDA slumped 229.86% — and 2024, when it jumped 860.87%.
• Sanara MedTech's EBITDA stood at -$3.1 million in 2022, then surged by 114.37% to $448909.0 in 2023, then jumped by 802.87% to $4.1 million in 2024, then rose by 15.73% to $4.7 million in 2025, then declined by 9.14% to $4.3 million in 2026.
• Business Quant data shows SMTI's EBITDA at $4.3 million in Q1 2026, $4.7 million in Q4 2025, and $4.9 million in Q3 2025.